- If you are wondering whether Veeva Systems at around US$178 a share still lines up with its underlying worth, you are not alone.
- The stock has had mixed returns, with a 3.9% decline over the past week, a 1.4% gain over the past month, and a 24.9% decline over the last year. The return over three years is around 0.5% lower and the five year return is 33.4% lower.
- Recent news coverage has focused on Veeva Systems as a long established player in life sciences software and on how investors are weighing its role in helping customers manage regulated data and workflows. Commentary has also highlighted how sentiment around higher growth software names has shifted, which frames how the market is currently treating Veeva Systems.
- Against that backdrop, Veeva Systems currently sits on a value score of 3 out of 6. The next sections will walk through standard valuation approaches before finishing with a way to put all these methods into a clearer overall picture of value.
Approach 1: Veeva Systems Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back to today using a required rate of return. It is essentially asking what those future dollars are worth in today’s terms.
For Veeva Systems, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $1.39b. Analyst forecasts and subsequent extrapolations out to 2035 point to projected free cash flows that reach around $3.13b in 2035, with Simply Wall St extending estimates beyond the initial analyst horizon.
When all those projected cash flows are discounted back, the resulting intrinsic value is about US$268.64 per share. Compared with the recent share price of around US$178, the DCF output suggests the stock is 33.6% undervalued on this model.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Veeva Systems is undervalued by 33.6%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks.
Approach 2: Veeva Systems Price vs Earnings
For profitable companies, the P/E ratio is a useful way to think about value because it links what you pay for each share directly to the earnings that company is currently generating. In general, higher expected growth and lower perceived risk can support a higher “normal” P/E, while slower growth and higher risk tend to justify a lower one.
Veeva Systems currently trades on a P/E of 32.0x. That sits above the Healthcare Services industry average of about 27.7x and also above the peer average of 29.6x. On the surface, that points to investors paying a higher price per dollar of earnings compared with many similar companies.
Simply Wall St’s Fair Ratio for Veeva Systems is 30.8x, which is the P/E level suggested after factoring in elements such as earnings growth, profit margins, industry, market cap and risk profile. This is more tailored than a simple comparison with peers or the broad industry because it attempts to align the multiple with the company’s own characteristics rather than relying on broad averages. Since the current P/E of 32.0x is above the Fair Ratio of 30.8x by more than 0.10, the stock screens as overvalued on this metric.
Result: OVERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Veeva Systems Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of Veeva Systems into a clear story that links the business context, a forecast for revenue, earnings and margins, and then a Fair Value you can compare with the current price. Each Narrative sits inside the Community page as an easy to use tool that updates when new news or earnings arrive. One investor might build a more optimistic Veeva Systems Narrative anchored to a Fair Value around US$380 based on higher growth and profitability, while another might lean on a more cautious Narrative closer to US$232.80. Seeing those side by side helps you decide for yourself whether the current share price near US$179 looks high, low or about right.
Do you think there's more to the story for Veeva Systems? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com